What could change its growth trajectory, and what would confirm it?
Innate Pharma's growth trajectory depends on clinical and regulatory advances in its proprietary ADC pipeline and the partnered therapy lacutamab. The company initiated a Phase 1 clinical trial of IPH4502. The U.S. Food and Drug Administration awarded lacutamab Breakthrough Therapy Designation for relapsed or refractory Sézary Syndrome.
The $75 million upfront sum, combined with private-placement proceeds, was projected to carry the company's projected cash runway through the end of Q1 2028.
Which risks could break the thesis, and what would warn of them?
The binding risk for Innate Pharma is financing: its operations depend on partner payments and equity proceeds to reach a stated cash runway. The company projected that the $75 million Sobi upfront payment together with private-placement proceeds would extend its cash runway through the end of Q1 2028.
Revenue from the monalizumab collaboration and licensing agreements was fully recognized from December 31, 2025, and no revenue was recognized for the six months ended June 30, 2026.
What does the product do for its buyer, and how is it delivered?
Innate Pharma offers cancer patients a clinical-stage oncology pipeline that pairs its own antibody-drug conjugates with late-stage antibodies developed through pharmaceutical partners. The company's proprietary pipeline centers on antibody-drug conjugates, led by IPH4502, a Nectin-4 ADC now in clinical development for solid tumors.
The partnered portion of that pipeline comprises two late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer.

A clinical-stage biotechnology company, Innate Pharma develops immunotherapies for cancer patients.